Insider Transactions in Q1 2023 at Century Therapeutics, Inc. (IPSC)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 23
2023
|
Luis Borges Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,597
-5.89%
|
$46,791
$3.55 P/Share
|
|
Mar 23
2023
|
Luis Borges Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
220,930
+45.5%
|
$220,930
$1.03 P/Share
|
|
Mar 22
2023
|
Luis Borges Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
65,698
-60.03%
|
$197,094
$3.72 P/Share
|
|
Mar 22
2023
|
Luis Borges Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
65,698
+37.51%
|
$65,698
$1.03 P/Share
|
|
Mar 21
2023
|
Luis Borges Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
63,616
-59.25%
|
$190,848
$3.77 P/Share
|
|
Mar 21
2023
|
Luis Borges Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,616
+37.21%
|
$63,616
$1.03 P/Share
|
|
Feb 02
2023
|
Adrienne Farid Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+17.09%
|
-
|
|
Feb 02
2023
|
Luis Borges Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+41.67%
|
-
|
|
Feb 02
2023
|
Douglas Carr SVP Finance & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+3.67%
|
-
|
|
Feb 02
2023
|
Michael Craig Diem Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+16.41%
|
-
|